| INTRODUCTION
Transcatheter Aortic Valve Replacement (TAVR) device design has evolved in an attempt to improve both device success rates and clinical outcomes. 1 However, aortic regurgitation (AR) is seen in up to 80% of patients following TAVR, affecting both the balloon-expandable and the self-expanding designs. 2 This typically reflects incomplete circumferential apposition between the circular prosthesis and the oval-shaped aortic annulus 3 and is often compounded by extensive calcification, under-expansion of the TAVR prosthesis or malposition. 4 Clinical trials and registry data have consistently shown that moderate or more paravalvular AR following TAVR is associated with reduced survival at short-and long-term term follow-up with all valve types. [5] [6] [7] Cardiovascular magnetic resonance (CMR) is the reference modality for assessing LV mass, volumes, and function. In addition, CMR permits full volumetric quantitation of AR that is highly accurate and reproducible, 8, 9 independent of the number or eccentricity of regurgitant jets, 10 and unlike echocardiography, is not limited by TAVR prosthesis or calcification artefact. 3 CMR has lower intra-observer and inter-observer variability than echocardiography 11, 12 and thus is more suited to serial measurements. Compared with CMR, echocardiography underestimates AR following TAVR 8, 13, 14 and thus CMR offers a potentially superior prognostic assessment of the post-TAVR patient. Scientific Lotus valve has a unique adaptive seal specifically designed to minimize post-TAVR aortic regurgitation (AR), 8 that has proven to be both safe and effective in the REPRISE I 15 and REPRISE II studies. 16 The aim of this study was to accurately quantify, using serial CMR, the degree of AR over time following TAVR using the first generation self-expanding Medtronic CoreValve, [17] [18] [19] [20] [21] and the second generation Boston Scientific Lotus valve, and to determine whether differences in aortic valve regurgitation and hemodynamics impact LV reverse remodeling.
2 | METHODS
| Study population
This non-randomized study prospectively recruited 59 patients with severe tri-leaflet degenerative AS who were referred for TAVR at the 
| CMR protocol
For each individual patient identical pre-and post-TAVR, and 6-month post-operative scans were performed at 1.5T (Intera or Ingenia, Phillips
Healthcare, Best, Netherlands) as previously described ( Figure 1 ). 25, 26 In brief, multi-slice, multi-phase cine imaging was performed using a standard steady-state free procession pulse sequence in the short axis FOV 340 mm). This position for imaging has been previously described and validated. 9 If significant turbulence or aliasing was seen in the velocity image, the acquisition was repeated a few millimeters further away from the valve, and/or with a higher-velocity window. In patients with AF, the use of multiple acquisitions and averaging of values, and the application of arrhythmia rejection (in which data points acquired from excessively long or short heart beats are rejected and reacquired)
were employed where feasible.
| CMR image analysis
Image analysis was performed in a blinded fashion, off-line using commercially available software (CVI42, Circle Cardiovascular Imaging, Calgary, Alberta, Canada) by two experienced observers. For LV mass and volumes, standard criteria were employed to delineate endocardial and epicardial borders at end-diastole and end-systole and values obtained were indexed to body surface area as previously described. 25 Papillary muscles were included within the LV cavity for the purpose of analysis and excluded from the LV mass. Aortic flow was quantified using cross-sectional phase contrast images with with standard grading criteria. 27 Intra-observer (12 random data sets 6 months apart) and inter-observer (12 data sets) agreement was assessed using the intra-class correlation coefficient.
| Sample size and statistical analysis
Based on published data 28 Table 1 .
| Measurement variability
Calculation of intra-class correlation coefficients indicated good intra- 
| Procedural data
All of the Lotus valves were implanted via the femoral artery, as were the majority of CoreValves (67% femoral, 29% subclavian, 4% direct aortic). The size and frequency of device replacement is detailed in Table 2 . Invasive resting trans-aortic pressure gradients were equivalent between the two groups, in keeping with baseline imaging.
The implant procedure for a Lotus valve involved significantly longer fluoroscopy times, despite a significantly greater proportion of CoreValve TAVR receiving post-dilatation (0% vs 28%, P = 0.003).
Equivalent volumes of contrast were used for each TAVR device (Table 2) . However, at the 6 month time-point, VARC defined success was equivalent between the two iterations; 91% Boston Lotus versus 89%
for Medtronic CoreValve (P = 0.827). The absolute rate of new pacemaker insertion was similar between the two groups (22% Lotus vs 15% CoreValve, P = 0.424).
| Hemodynamics
The severity of pre-operative aortic valve stenosis was similar between the Lotus and CoreValve groups (Table 1) vs19.7 ± 10.5 mmHg, P = 0.332) ( Table 3) . (Figure 3 ). Between the immediate and 6 month scans, the aortic regurgitant fraction in the Lotus group remained unchanged (4.0 ± 3.5 vs 5.6 ± 5.3%, P = 0.267).
However, a significant reduction was observed in the CoreValve patients (11.7 ± 7.2 vs 6.4 ± 5.0%, P = 0.002) ( Figure 5B ). As such, comparison between CoreValve and Lotus patients at 6 months showed that the residual total aortic regurgitant fraction was equivalent (6.4 ± 5.0 vs 5.6 ± 5.3%, respectively, P = 0.623) (Table 3) .
Importantly, of the 19 CoreValve patients who were imaged at 6 months, all of the seven patients with ≥moderate AR immediately post-TAVR reduced to only mild AR, while three changed from mild to none/trivial AR. There were no Lotus valve patients with ≥moderate AR at any time point (Figure 4 ).
| LV reverse remodeling
There were no significant differences in indexed LV end diastolic indexed LVEDV values at 6 months were unchanged, regardless of the valve type. However, at 6 months, a significant and comparable regression in the indexed LV mass was observed in both TAVR groups (Table 4 , Figures 5C and 5D ).
| DISCUSSION
This is the first study to use CMR to directly and systematically compare two distinct TAVR designs for aortic valve regurgitation, hemodynamics, and impact on LV reverse remodeling over time. The principal findings were as follows: (1) 
TAVR with the Medtronic
CoreValve is associated with a significantly greater quantity of aortic 
| Procedural success
In direct comparison, the VARC-defined primary composite outcome of device success was significantly higher in the Lotus group at the immediate post-TAVR time point, driven principally by the absence of ≥moderate aortic regurgitation. The Lotus valve has been compared with the CoreValve previously using echocardiography 1 ; however these grading criteria suggested by VARC lack validation post-TAVR. 31 In a recent comparison of 2D and 3D echocardiography and CMR, applying VARC metrics post-TAVR, the observer variability in determining AR was superior by CMR. 12 This is the first study to our knowledge to assess device success using CMR, and using VARC criteria suggests superiority of the Lotus valve over CoreValve immediately post deployment. However, device success by the 6 month time point in our study was equivalent.
| Aortic regurgitation following TAVR
There is growing evidence suggesting a significant association of postprocedural AR with short-and long-term mortality. 18, 32, 33 In a metaanalysis of 12 926 patients from 45 studies (a majority using Edwards SAPIEN devices), moderate or more AR was associated with a 2.3-fold increase in 1 year mortality following TAVR. 34 Our study used CMR to study the evolution of AR over time. No significant change was seen in the Lotus group from post-implant to 6 months, in line with REPRISE I 15 and REPRISE II. 16 However, we did observe a significant reduction in AR at 6 months following CoreValve replacement. This is consistent with prior echocardiography studies, including the multicenter CoreValve US Pivotal Trial which indicated over 80% of patients exhibited an improvement of at least one grade of regurgitation at 1 year. 35 A recent CMR study did suggest a small increase in AR at 6 months post-TAVR; but this study combined measurements of the CoreValve with those of another TAVR design. 36 Our study is the first
to use CMR to demonstrate a significant and clinically important improvement in AR over time; all patients with at least moderate AR immediately post-TAVR having mild or less at 6 months. This may reflect continued outward expansion of the nitinol CoreValve frame, 35 in contrast to the fixed mechanically locked Lotus frame. Interestingly, analysis of the large UK TAVR registry showed ≥moderate AR after
CoreValve, in contrast to the SAPIEN valve, was not associated with increased long-term mortality, 37 our finding that ≥moderate AR post-TAVR had resolved at 6 months in all cases may explain these findings. comparable to those reported in previous echocardiographic studies. 16 We do not have effective orifice area information as CMR does not permit accurate assessments in this context. Hence the degree of patient -prosthesis mismatch in our study remains unclear and would further clarify whether the pressure gradients represent poor individual sizing or a genuine reflection of TAVR design.
| TAVR pressure gradients

| LV reverse remodeling
A significant finding of this study is the acute regression in LV mass index observed following the CoreValve but not the Lotus. Our group has previously reported acute reverse remodeling following TAVR with an average reduction in 8 g/m 2 seen within the first week. 38 In a substudy of the PARTNER A trial, a notable portion of patients exhibited mass regression within the first 30 days. 39 These findings may have clinical implications given that early LV mass regression following TAVR is associated with improved diastolic function, 40 lower B-type Natriuretic Peptide levels and reduced readmission to hospital for heart failure. 39 The difference in immediate LV mass regression post TAVR may well be a consequence of the pressure gradients measured;
with comparable reverse remodeling observed at 6 months when pressure gradients were similar. Given that the degree of LV mass regression and recovery of diastolic function after TAVR are positive prognostic indicators 41, 42 and residual hypertrophy detrimental, 43 further work to validate these findings is merited.
| Limitations
This was a small single-center non-randomized comparison. Only patients clinically stable enough to participate in the CMR study were included. Not all patients were able to complete the 6 month scan, predominantly due to pacemaker replacement or death, which may have introduced bias, although the final analyzed population did not differ from the recruited population in terms of demographics and comorbidities. Our study did include patients in atrial fibrillation (18% in total) in whom there was potential quantification error. While the 20 We used CMR to quantify the total AR seen following TAVR, which is a composite of para-valvular and trans-valvular regurgitation.
Total aortic regurgitation following TAVR has been demonstrated as an important marker of mortality 45 and central trans-valvular regurgitation is usually minor and a physiological feature by virtue of prosthesis design. 31 Furthermore, the VARC-2 criteria advocate a combined measurement of "total" aortic regurgitation (AR) reflecting the total regurgitant volume load imposed on the LV. 44 Finally, this study utilized a different grading scale for aortic regurgitant fraction to that advocated by VARC-2, which is based primarily on data from native valve AR measurements. Our values are however entirely consistent with studies focusing on AR specifically after TAVR. 
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